BRAF, RAF1: B-raf/RAF proto-oncogene serine/threonine-protein kinase
Family in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on BRAF, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Naporafenib | Phase 3 | Erasca | Small molecule | InhibitorB-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | 4 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Naporafenib | Phase 3 | Active, not recruiting | Erasca, Inc. | Apr 3, 2024 |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | Naporafenib | Phase 1 | Active, not recruiting | Erasca, Inc. | Jun 18, 2023 |
| Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Naporafenib | Phase 2 | Active, not recruiting | Novartis Pharmaceuticals | Jun 4, 2020 |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | Naporafenib | Phase 1 | Active, not recruiting | Novartis Pharmaceuticals | Nov 6, 2017 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3883317, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets